| Bioactivity | Magrolimab (Hu5F9-G4) is a first-in-class humanized anti-CD47 IgG4 antibody with an anti-tumor activity[1]. |
| Name | Magrolimab |
| CAS | 2169232-81-7 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Caner Saygin, et al. Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021 Jul;48:100791. |